TSX:DHT.UN - Post by User
Post by
retiredcfon Sep 10, 2023 1:55pm
168 Views
Post# 35628367
Assessment
Assessment Could you please supply the current numbers and information for DHT.UN, along with your commentary about what they lead you to conclude about its current health and future prospects?
Distribution/free cash flow (2022) 41%; the company has added $253M in royalty deals since Q1 2023 (towards its $900M target by 2025). EBITDA margin is 83%. With the company in high growth mode the EBITDA multiple is very high and not that meaningful yet. FCF mutliple is about 6X. The outlook looks fine. The portfolio duration is now 10 years, and management notes it has 16 near-term deals potentially and 10 more longer term possible deals. Its Orserdu drug (acquired in June) has good world-wide potential. The stock is tightly held (four entities own 40%) and thus can move nicely when buying comes in. It is having a very good year yet still has potential. We would not expect the same rate of return going forward, and EPS may did slightly next year. But the company is building a solid business, paying special dividends and doing many things right. (5iResearch)